Free Stock & ETF Comparisons

Compare Kenvue and Colgate-Palmolive by brand quality, Hill's Pet Nutrition growth, dividend history, and consumer staples income investing.

Compare Accolade and Teladoc by employer digital health strategy, BetterHelp mental health, member engagement, and virtual care investing.

Compare Walgreens and CVS by pharmacy retail strategy, PBM business, Aetna insurance, and integrated healthcare investing.

Compare Johnson & Johnson and Merck by drug pipeline depth, oncology revenue, medical device strength, dividend growth, and long-term shareholder value.

Compare Pfizer and Merck by drug pipeline, oncology and vaccine revenue, post-COVID recovery, dividend sustainability, and analyst upside.

Compare Johnson & Johnson and GSK by vaccine portfolio, oncology pipeline, MedTech vs consumer health strategy, dividend growth, and valuation.

Compare Pfizer and AstraZeneca by oncology pipeline strength, rare disease growth, mRNA platform potential, international market presence, and analyst upside.

Compare Bristol-Myers Squibb and AstraZeneca by cancer drug revenue, immune-oncology pipeline, blood thinner competition, international growth, and valuation.

Compare Eli Lilly and Regeneron by GLP-1 obesity drug revenue, Dupixent vs Mounjaro growth trajectory, pipeline breadth, operating margins, and analyst upside.

Compare AbbVie and Amgen by immunology drug revenue, biosimilar exposure, post-Humira pipeline strength, dividend yield, and long-term valuation.

Compare Gilead Sciences and Regeneron by HIV franchise durability, oncology pipeline, Dupixent vs Lenacapavir revenue momentum, margins, and analyst upside.

Compare Amgen and Gilead Sciences by biosimilar defense, HIV franchise durability, obesity drug pipeline, dividend yield, and long-term value.

Compare Amgen and Biogen by biosimilar competition, pipeline depth, Alzheimer's drug momentum, obesity drug ambitions, dividend yield, and valuation.

Compare Vertex Pharmaceuticals and Biogen by cystic fibrosis monopoly, Alzheimer's drug momentum, rare disease pipeline, margins, and analyst upside.

Compare Repligen and Alnylam by bioprocessing revenue recovery, RNA interference drug pipeline, clinical breadth, operating margins, and analyst upside.

Compare Edwards Lifesciences and Boston Scientific by TAVR adoption, electrophysiology revenue, structural heart pipeline, operating margins, and analyst upside.

Compare Edwards Lifesciences and Medtronic by structural heart market share, pacemaker and CGM revenue, international device growth, margins, and analyst upside.

Compare Abbott Laboratories and Zimmer Biomet by CGM market growth, orthopedic implant volumes, robotic surgery pipeline, margins, and analyst upside.

Compare Becton Dickinson and Thermo Fisher by diagnostics and biosciences growth, recurring revenue mix, margins, acquisition strategy, and long-term value.

Compare Becton Dickinson and Johnson & Johnson by diagnostics revenue, MedTech breadth, drug pipeline vs device growth, dividend history, and valuation.

Compare Cigna and Humana by Medicare Advantage enrollment, pharmacy benefit management, medical loss ratio, revenue growth, and analyst upside.

Compare IQVIA and ICON by clinical research outsourcing market share, data analytics platform differentiation, biotech vs pharma customer mix, backlog conversion, and which CRO offers better exposure to drug development.

Compare Teladoc and American Well by virtual care utilization, platform integration depth, mental health and chronic care revenue, path to profitability, and which telehealth company offers better recovery potential.

Compare Hims & Hers and Teladoc by GLP-1 weight loss momentum, subscription vs enterprise revenue model, customer acquisition cost, margin trajectory, and which digital health platform offers better long-term upside.

Compare Molina Healthcare and UnitedHealth by Medicaid vs commercial health insurance exposure, medical loss ratio management, government contract revenue stability, and long-term managed care growth potential.

Compare CVS Health and Cigna by pharmacy benefits management market share, integrated care model, Evernorth vs Oak Street revenue, margin recovery trajectory, and which health services company offers better long-term value.

Compare HCA Healthcare and Universal Health Services by hospital vs behavioral health network, reimbursement rate trends, volume growth, operating leverage, and which hospital operator offers better margin expansion potential.

Compare Baxter and Becton Dickinson by portfolio restructuring progress, IV solutions vs diagnostics revenue, hospital supply chain positioning, debt reduction pace, and which medical supply company offers better recovery upside.

Compare Thermo Fisher Scientific and West Pharmaceutical Services by bioproduction revenue, drug delivery component growth, biopharma customer concentration, margin profile, and which life science services company offers better value.

Compare McKesson and Cardinal Health by pharmaceutical distribution market share, specialty pharmacy growth, oncology services network, operating efficiency, and which drug wholesaler offers better long-term margin expansion.

Compare IQVIA and Medpace by full-service vs niche CRO positioning, biotech vs pharma customer concentration, EBITDA margin structure, backlog coverage ratio, and which clinical research company offers better risk-adjusted growth.

Compare Zimmer Biomet and Boston Scientific by orthopedic vs cardiovascular device market share, robotic surgery platform investment, international revenue mix, and which medical device company offers better long-term growth.

Compare Philips and Medtronic by imaging and patient monitoring vs cardiac rhythm management, recall resolution progress, software-enabled device strategy, international exposure, and long-term innovation pipeline.

Compare Abbott and DexCom by continuous glucose monitoring market share, Libre vs G7 sensor technology, non-diabetes CGM opportunity, device plus pharmaceutical portfolio diversification, and long-term diabetes care growth.

Compare GE HealthCare and Medtronic by medical imaging vs device revenue, AI diagnostic software investment, hospital vs outpatient channel mix, new product pipeline, and which healthcare equipment company offers better long-term upside.

Compare Gilead and Vertex by durable revenue moats, oncology and gene therapy pipeline depth, free cash flow generation, capital allocation, and which biotech compunder offers better long-term value.

Compare Moderna and Vertex by platform technology durability, COVID vaccine revenue decline vs CF monopoly stability, pipeline breadth, cash runway, and which biotech approach offers better long-term investment returns.

Compare AbbVie and Regeneron by post-Humira growth transition, Skyrizi and Rinvoq ramp, Dupixent label expansion, oncology pipeline, and which large-cap biotech offers better earnings visibility through 2030.

Compare Amgen and Regeneron by biosimilar exposure, GLP-1 obesity drug pipeline (MariTide), Dupixent vs Enbrel replacement, free cash flow, and which established biotech offers better risk-adjusted long-term returns.

Compare Biogen and Alnylam by Alzheimer's disease therapy validation, RNA interference platform breadth, pipeline conversion rate, revenue trajectory, and which biotech platform offers better long-term growth potential.

Compare Gilead and Moderna by revenue durability, pipeline diversification, cash generation vs cash burn, platform reinvestment, and which large biotech strategy — franchise cash flow or platform moonshot — offers better returns.

Compare Vertex Pharmaceuticals and BioMarin by rare disease franchise depth, gene therapy pipeline, pricing power, geographic expansion opportunity, and which rare disease biotech offers better long-term compounding.

Compare Ultragenyx and Biogen by rare disease pipeline breadth, commercialization risk, platform technology (gene vs antibody), pathway to profitability, and which biotech offers better near-term catalysts.

Compare Editas and Intellia Therapeutics by CRISPR vs base editing strategy, in vivo delivery progress, clinical pipeline advancement, partnership quality, and which gene editing company offers better long-term upside.

Compare Beam Therapeutics and Intellia by base editing vs CRISPR technology approach, clinical data readouts, cash runway, pipeline breadth, and which next-generation gene editing platform offers better investment potential.

Compare AbbVie and Roche ADR by oncology drug pipeline depth, post-patent cliff transition, HER2 and immunology franchises, dividend yield, and which large-cap pharma offers better defensive income with growth.

Compare Roche and Novartis ADRs by oncology vs cardiovascular drug leadership, diagnostics revenue mix, gene therapy pipeline investment, shareholder return programs, and which Swiss pharmaceutical giant offers better long-term value.

Compare PTC Therapeutics and BioMarin by Duchenne muscular dystrophy and PKU drug portfolios, regulatory pathway history, revenue growth trajectory, and which mid-cap rare disease biotech offers better risk-adjusted returns.